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Abstract
Background: A high incidence of severe hematological adverse events during sunitinib treatment complicates
decision making on dose and treatment cycle. We identified the characteristics of early-onset hematotoxicity of
sunitinib in Japanese patients with renal cell carcinoma (RCC).
Methods: Seventy-nine patients were treated with sunitinib as 6-week cycles of “4-week on 2-week off” schedule.
To evaluate early-onset hematotoxicity, we compared patients with dose reduction during the first cycle (dose-
reduced group, n = 57) and those who maintained the initial dose (dose-maintained group, n = 22). ABCG2 and
FLT3 genotypes were analyzed for association between hematotoxicity and reported gene polymorphisms.
Results: Mean relative dose intensity (RDI) was similar in the two groups during the first 2 weeks of dosing in the
first cycle, but was significantly lower in the dose-reduced group during the last 2 weeks. Lymphocytopenia and
thrombocytopenia were observed in the dose-reduced group within the first 2 weeks. Genetic analysis indicated a
significantly higher frequency of FLT3 738 T/C polymorphism in the dose-reduced group, but no significant
difference in the ABCG2 421 C/A polymorphism.
Conclusions: This study showed a high incidence of sunitinib-induced hematotoxicity in Japanese patients with
RCC, many of whom need dose adjustment during the first cycle. Further studies should verify whether dose
adjustment based on early-onset thrombocytopenia prolongs sunitinib treatment.
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Background
Sunitinib, an orally administered tyrosine kinase inhibi-
tor (TKI), has been evaluated in a randomized phase 3
trial in comparison with interferon alfa in patients with
metastatic renal cell carcinoma (RCC) [1]. Their study
demonstrated that sunitinib was superior to interferon
alfa in prolonging progression-free survival (PFS) and
maintaining quality of life. Recent studies showed that
Asian populations had more sunitinib-induced adverse
events than Caucasian patients [2–4]. A subgroup ana-
lysis of Japanese patients showed prolongation of PFS
but more hematological adverse events [5]. A post-
marketing surveillance study in Japan found that the
most common adverse event was a laboratory test
abnormality and that severe adverse events occurred
within 4 weeks after starting sunitinib [6]. In the clinical
setting, Japanese patients have difficulties maintaining
the original “4-week on 2-week off” dosing regimen
because of a high incidence of adverse events.
Pharmacokinetic and pharmacodynamic factors are
supposed to affect the toxicity of sunitinib. A previous
pharmacokinetic study has shown that ATP-binding
cassette, sub-family G, member 2 (ABCG2) 421 C/A, the
most common mutant allele among ABCG2 poly-
morphisms in Japanese population [7, 8], is associated
with increased exposure of sunitinib [9, 10]. Fms related
tyrosine kinase 3 (FLT3) is a pharmacodynamic gene and
one of the kinases targeted by sunitinib, and the asso-
ciation between the FLT3 738 T/C polymorphism
and sunitinib-induced bone marrow toxicity has been
reported [11, 12].
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The aim of the present study was to evaluate the
characteristics of hematological toxicity of sunitinib in
Japanese patients with RCC and to identify the relation-
ship between the relative dose intensity (RDI) during the
first cycle and early-onset of hematological toxicity.
Methods
Patients
Seventy-nine patients treated with sunitinib between
June 2008 and March 2015 at the Iwate Medical Univer-
sity were analyzed. All patients received 6-week cycles
with a “4-weeks on 2-weeks off” schedule. During ther-
apy, dose interruption and reduction were permitted if
severe adverse event occurred. To determine RDI, suni-
tinib 50 mg/day with a 4-week on and 2-week off sched-
ule was considered the planned therapy based on the
Pharmaceuticals and Medical Devices Agency (PMDA)-
approved dose/schedule for RCC. The institutional review
board of our institution approved the present study (ap-
proval number: H26–91). Analysis of gene polymorphism
was performed in patients who gave informed consent.
Laboratory assessments
Blood samples were collected at baseline and on days
7, 14, 21, 28, and 42 during the first cycle. Bone
marrow function, renal function (serum creatinine),
liver function and other laboratory tests were con-
ducted. Laboratory abnormalities were scored according
to the criteria of Common Toxicity Criteria for Adverse
Events (CTCAE) version 4.0. To evaluate clinical fe-
atures of early-onset hematotoxicity, we compared
blood and serum data in patients who required dose
reduction or discontinuation during the first cycle
(dose-reduced group), and patients who maintained
the starting dose throughout the first cycle (dose-
maintained group).
Analysis of polymorphism
To examine the relationship between hematotoxicity
and reported gene polymorphisms, 36 patients who gave
informed consent were analyzed for the ABCG2 geno-
type associated with high sunitinib exposure, and for the
FLT3 genotype which was reported to be related to
sunitinib-induced myelosuppression.
Blood samples were collected in heparinized tubes and
frozen (−80 °C) until required for assay. Probes and
primers for typing each SNP by TaqMan SNP genotyp-
ing assays were synthesized by Thermo Fisher Scientific
(Waltham, MA). Real-time PCR with cycle reactions of
10 min at 95 °C followed by 57 cycles of 15 s at 92 °C,
60 s at 60 s, and 5 min at 50 °C was performed for reac-
tion mixtures containing sample DNA, probes, and
primers in 96-well plates with a LightCycler 480 (F.
Hoffmann-La Roche, Basel, Switzerland). SNP calls were
done by an in-house software of SNP Data Viewer v3.1
(System Biotics, Sagamihara, Japan).
Data analysis
Laboratory abnormalities graded according to CTCAE
were analyzed using the Pearson test and Fisher test.
Changes in laboratory data from baseline were assessed
using a paired t-test or an exact paired Wilcoxon test.
Fisher’s exact test or chi-square test and t-test were used
to compare patient characteristics. P values less than
0.05 were considered statistically significant. To deter-
mine RDI, sunitinib at 50 mg/day with a 4-week on and
2-week off schedule was considered the planned therapy
based on the PMDA-approved dose/schedule for RCC.
Time to treatment failure (TTF) was estimated by the
Kaplan-Meier method, and log-rank test was used to
compare TTF between groups. P values less than 0.05
were considered statistically significant.
Results
Patients
The subjects comprised 55 men and 24 women with a
median age of 68 (range 39–82) years. Sixty-two patients
had a Karnofsky performance status (KPS) rating of
80%–100% (mean 90.8% ± 1.7%) at the start of sunitinib
treatment. According to the Memorial Sloan-Kettering
Cancer Center (MSKCC) risk criteria [1], 23 patients
(29%) were classified as poor risk. The most common
sites of metastases were the lungs and lymph nodes.
Forty-one patients had received a prior nephrectomy,
while 5 patients received cytoreductive nephrectomy
following administration of sunitinib. Histology showed
clear cell RCC in 47 patients (Fig. 1) and papillary RCC
in one patient. Sunitinib was given as first-line therapy
in 64 patients. As a starting dose, 56 patients were
Fig. 1 Histological clear cell subtype. Obtained from a patient who
received cytoreductive nephrectomy following sunitinib therapy.
Objective magnification: 400×
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administered sunitinib at 50 mg, while 23 patients were
given lower doses at the discretion of clinical doctors.
During the first cycle, 22 patients (28%) maintained the
starting dose while 57 patients (72%) required reduction
or discontinuation of sunitinib due to adverse events.
The mean RDI of sunitinib for the last 2 weeks of dosing
in the first cycle was significantly lower than that for the
first 2 weeks (47.1% versus 84.9%, p < 0.01).
Hematotoxicity
Laboratory abnormalities during the first cycle and weeks
0–2 of the first cycle are shown in Table 1. Seventy-two
percent of all patients had low hemoglobin, and 61% had
hypoalbuminemia before the initiation of sunitinib ther-
apy. The most common adverse hematological events
were hypoalbuminemia (95%), platelet count decreased
(87%), hemoglobin decreased (85%), and Aspartate ami-
notransferase (AST) increased (73%) during the first
cycle. Compared with the baseline, the number of all
adverse events other than hyperuricemia increased sig-
nificantly during therapy. The most common moderate
(grade 2) and severe (grades 3 and 4) adverse events
were hemoglobin decreased (54%), hypoalbuminemia
(51%), and platelet count decreased (43%).
Table 1 Laboratory abnormalities
All Grades n (%) Grade 1 n (%) Grade 2 n (%) Grade 3/4 n (%) p value
White blood cell count decreased pretreatment 2 (3) 2 (3) 0 (0) 0 (0)
0-2 week of first cycle 10 (13) 4 (5) 6 (8) 0 (0) 0.10
First cycle 44 (56) 12 (15) 27 (34) 5 (6) <0.01
Neutrophil count decreased pretreatment 1 (1) 1 (1) 0 (0) 0 (0)
0-2 week of first cycle 4 (5) 4 (5) 0 (0) 0 (0) 0.56
First cycle 33 (42) 12 (15) 18 (23) 3 (4) <0.01
Lymphocyte count decreased pretreatment 22 (28) 13 (16) 7 (9) 2 (3)
0-2 week of first cycle 40 (51) 11 (14) 8 (10) 11 (14) <0.01
First cycle 46 (58) 18 (23) 12 (15) 16 (20) <0.01
Hemoglobin decreased pretreatment 57 (72) 34 (43) 15 (19) 8 (10)
0-2 week of first cycle 52 (67) 31 (39) 18 (23) 3 (4) 0.30
First cycle 67 (85) 24 (30) 28 (35) 15 (19) <0.01
Platelet count decreased pretreatment 9 (11) 9 (11) 0 (0) 0 (0)
0-2 week of first cycle 45 (57) 35 (44) 6 (8) 4 (5) <0.01
First cycle 69 (87) 33 (42) 20 (25) 16 (21) <0.01
Creatinine increased pretreatment 29 (36) 26 (33) 2 (3) 1 (1)
0-2 week of first cycle 46 (58) 42 (53) 4 (5) 0 (0) 0.04
First cycle 46 (58) 41 (52) 4 (5) 1 (1) 0.02
Aspartate aminotransferase increased pretreatment 12 (15) 12 (15) 0 (0) 0 (0)
0-2 week of first cycle 42 (53) 34 (43) 6 (8) 2 (3) <0.01
First cycle 58 (73) 47 (59) 7 (9) 4 (5) <0.01
Alanine aminotransferase increased pretreatment 16 (20) 16 (20) 0 (0) 0 (0)
0-2 week of first cycle 33 (42) 28 (35) 4 (5) 1 (1) <0.01
First cycle 55 (70) 45 (57) 5 (6) 5 (6) <0.01
Hypoalbuminemia pretreatment 48 (61) 28 (35) 18 (23) 2 (3)
0-2 week of first cycle 69 (87) 33 (42) 30 (38) 6 (8) <0.01
First cycle 75 (95) 27 (34) 38 (48) 10 (13) <0.01
Blood bilirubin increased pretreatment 0 (0) 0 (0) 0 (0) 0 (0)
0-2 week of first cycle 3 (4) 3 (4) 0 (0) 0 (0) 0.36
First cycle 6 (8) 5 (6) 0 (0) 1 (1) 0.02
Amylase increased pretreatment 19 (24) 16 (20) 3 (4) 0 (0)
0-2 week of first cycle 29 (37) 19 (24) 8 (10) 2 (3) 0.03
First cycle 42 (53) 20 (25) 11 (14) 11 (14) <0.01
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In all subjects, the mean dose during the last 2 weeks
of dosing in the first cycle decreased significantly. There-
fore, we analyzed the adverse events with early onset
(within the first 2 weeks of dosing). The most common
early-onset adverse hematological events were hypoalbu-
minemia (87%), hemoglobin decreased (67%), creatinine
increased (58%), platelet count decreased (57%), AST
increased (53%), and lymphocyte count decreased (51%).
Among these adverse events, the incidence rate of
hemoglobin decreased but was not significantly different
compared with the baseline data.
Analysis of dose-maintained and dose-reduced groups
To evaluate the clinical features of early-onset hema-
totoxicity related to dose reduction, we performed an
analysis by dividing the patients into a dose-reduced
group (n = 57) and a dose-maintained group (n = 22).
Patient characteristics of the two groups are summa-
rized in Table 2. Patient background did not differ sig-
nificantly between the two groups. Analysis of patient
characteristics showed an older age and lower body
surface area (BSA) in the dose-reduced group than in
the dose-maintained group while the starting dose was
similar in the two groups. The mean RDI during the
first 2 weeks of dosing was similar in the two groups
(83.9% ± 2.6% versus 87.5% ± 4.2%, p = 0.47) although
the mean RDI during the last 2 weeks was significantly
lower in the dose-reduced group than in the dose-
maintained group (31.0% ± 3.4% versus 88.6% ± 5.5%,
p < 0.01).
Adverse events of the two groups are shown in Table 3.
The numbers of all adverse events increased during the
first cycle in both groups. On day 14 of the first
cycle, the lymphocyte and platelet count decreased
which occurred significantly more frequently in the
dose-reduced group.
Laboratory data of lymphocyte and platelet counts in
the two groups are shown in Table 4. The mean lympho-
cyte count in the dose-reduced group was significantly
lower than in the dose-maintained group on day 14
(887/m2 versus 1405/m2, p < 0.01), but increased grad-
ually to a similar level by the end of the first cycle.
The mean platelet count in the dose-reduced group
was significantly lower on day 14 (15.9 × 104/m2 versus
22.0 × 104/m2, p < 0.01), but recovered gradually follow-
ing dose reduction or discontinuation. On the other
hand, the platelet count in the dose-maintained group
decreased gradually and was significantly lower than in
the dose-reduced group on day 28 (11.6 × 104/m2 versus
16.8 × 104/m2, p = 0.01).
Thirty-three patients in the dose-reduced group con-
tinued sunitinib treatment for the second cycle. The
mean RDI during the whole second cycle was similar to
that during the first cycle (61.2% versus 65.9%, p = 0.26).
The mean RDI for the last 2 weeks of dosing in the
second cycle was significantly higher than that in the
first cycle (57.5% versus 43.1%, p = 0.02). In these pa-
tients, the mean thrombocyte count during the second
cycle was stable (first 2 weeks; 22.5 × 104/m2, last
2 weeks; 22.0 × 104/m2, p = 0.81).
Table 2 Patient characteristics of the two groups
Characteristics Dose-reduced group Dose-maintained group Univariate analysis
n = 57 n = 22 p value
Sex (men), n (%) 38 (66.7) 17 (77.3) 0.42
Mean age ± 2SD, year 67.2 ± 9.7 62.1 ± 10.1 0.04
Mean KPS ± 2SD, % 91.1 ± 15.4 90.5 ± 14.6 0.87
Mean BMI ± 2SD, kg/m2 21.9 ± 3.3 24.1 ± 4.5 0.05
Mean BSA ± 2SD, m2 1.6 ± 0.2 1.7 ± 0.2 <0.01
Concomitant CYP3A4 metabolized drug, n (%) 27 (47) 12 (55) 0.62
MSKCC risk score, n Favorable/Intermediate/Poor 4/36/17 2/14/6 0.94
Histological clear cell subtype, n (%) 32 (56) 15 (68) 0.77
Prior nephrectomy, n (%) 29 (51) 12 (55) 0.90
Common sites of metastasis, n (%) Lung 29 (51) 16 (73) 0.13
Bone 15 (26) 5 (23) 1.00
Liver 6 (11) 2 (9) 1.00
Lymph node 18 (32) 6 (27) 0.79
Starting dose 50/37.5/25 mg, % 72/21/7 68/14/18 0.29
RDI during the first two weeks of dosing, mean ± 2SE, % 83.9 ± 2.6 87.5 ± 4.2 0.47
RDI during the last two weeks of dosing, mean ± 2SE, % 31.0 ± 3.4 88.6 ± 5.5 <0.01
KPS Karnofsky performance status scale, BMI body mass index, BSA body surface area, MSKCC MemorialSloan–Kettering Cancer Centre, RDI relative dose intensity
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Table 3 Laboratory abnormalities of the two groups
















pretreatment 2 (3) 2 (3) 0 (0) 0 (0) 0 (0) 0 (0) 1.00
First 2 weeks 10 (18) 10 (18) 0 (0) 0 (0) 0 (0) 0 (0) 0.05
First cycle 33 (58) 29 (51) 4 (7) 11 (50) 10 (46) 1 (5) 0.61
Neutrophil count
decreased
Pretreatment 1 (2) 1 (2) 0 (0) 0 (0) 0 (0) 0 (0) 1.00
First 2 weeks 3 (5) 3 (5) 0 (0) 1 (5) 1 (5) 0 (0) 1.00
First cycle 26 (46) 24 (42) 2 (3) 7 (32) 6 (27) 1 (5) 0.58
Lymphocyte count
decreased
pretreatment 17 (30) 15 (27) 2 (3) 5 (23) 5 (23) 0 (0) 0.58
First 2 weeks 28 (49) 17 (30) 11 (19) 2 (9) 2 (9) 0 (0) <0.01
First cycle 37 (65) 21 (37) 16 (28) 9 (41) 9 (41) 0 (0) 0.13
Hemoglobin decreased pretreatment 43 (75) 38 (67) 5 (9) 14 (65) 11 (50) 3 (14) 0.40
First 2 weeks 38 (67) 35 (61) 3 (5) 14 (65) 14 (65) 0 (0) 0.80
First cycle 48 (84) 36 (63) 12 (21) 2 (9) 2 (9) 0 (0) 1.00
Platelet count decreased pretreatment 7 (12) 7 (12) 0 (0) 9 (41) 9 (41) 0 (0) 1.00
First 2 weeks 37 (65) 34 (60) 3 (5) 8 (37) 7 (32) 1 (5) 0.03
First cycle 50 (89) 36 (64) 14 (25) 19 (86) 17 (77) 2 (9) 1.00
Creatinine increased pretreatment 21 (37) 20 (36) 1 (2) 8 (36) 8 (36) 0 (0) 1.00
First 2 weeks 33 (58) 33 (58) 0 (0) 13 (59) 13 (59) 0 (0) 1.00
First cycle 33 (58) 32 (56) 1 (2) 13 (59) 13 (59) 0 (0) 1.00
Aspartate aminotransferase
increased
pretreatment 10 (18) 10 (18) 0 (0) 2 (9) 2 (9) 0 (0) 0.49
First 2 weeks 34 (61) 32 (56) 2 (4) 8 (36) 8 (36) 0 (0) 0.08
First cycle 45 (79) 43 (76) 2 (4) 13 (59) 11 (50) 2 (9) 0.09
Alanine aminotransferase
increased
pretreatment 13 (23) 13 (23) 0 (0) 3 (14) 3 (14) 0 (0) 0.53
First 2 weeks 26 (46) 25 (44) 1 (2) 7 (32) 7 (32) 0 (0) 0.79
First cycle 39 (68) 36 (63) 3 (5) 16 (73) 14 (64) 2 (9) 0.89
Hypoalbuminemia pretreatment 38 (67) 37 (65) 1 (2) 10 (45) 9 (41) 1 (5) 0.12
First 2 weeks 52 (92) 48 (84) 4 (7) 17 (77) 15 (68) 2 (9) 0.24
First cycle 54 (95) 46 (81) 8 (14) 21 (95) 19 (86) 2 (9) 1.00
Blood bilirubin increased pretreatment 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) N.D.
First 2 weeks 2 (4) 2 (4) 0 (0) 1 (5) 1 (5) 0 (0) 1.00
First cycle 4 (7) 3 (5) 1 (2) 2 (9) 2 (9) 0 (0) 0.67
Amylase increased pretreatment 15 (26) 15 (27) 0 (0) 4 (18) 4 (18) 0 (0) 0.57
First 2 weeks 23 (40) 21 (37) 2 (4) 6 (27) 6 (27) 0 (0) 0.42
First cycle 33 (58) 23 (41) 10 (18) 9 (41) 8 (36) 1 (5) 0.20
Hyperuricemia pretreatment 10 (18) 10 (18) 0 (0) 6 (27) 6 (27) 0 (0) 0.54
First 2 weeks 14 (25) 14 (25) 0 (0) 5 (23) 5 (23) 0 (0) 1.00
First cycle 14 (25) 14 (25) 0 (0) 7 (32) 7 (32) 0 (0) 0.57
Hypophosphatemia pretreatment 4 (7) 2 (4) 2 (4) 3 (14) 2 (9) 1 (5) 0.40
First 2 weeks 10 (18) 8 (15) 2 (4) 0 (0) 0 (0) 0 (0) 0.05
First cycle 26 (46) 21 (37) 5 (9) 8 (36) 7 (32) 1 (5) 0.60
Data are expressed in number of cases, with percentage in parenthesis
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We also conducted analysis of patients with clear cell
RCC. Patients with clear cell RCC were divided into a
dose-reduced group (n = 32) and a dose-maintained
group (n = 15). The patient background did not differ
significantly between the two groups. In both groups,
approximately 80% of patients received a prior nephrec-
tomy. The mean RDI during the first 2 weeks of dosing
was similar in the two groups (86.7% ± 3.1% versus
93.3% ± 3.8%, p = 0.19) although the mean RDI during
the last 2 weeks was significantly lower in the dose-
reduced group than in the dose-maintained group
(30.8% ± 5.1% versus 95.0% ± 2.7%, p < 0.01).
The numbers of all adverse events increased during
the first cycle in both groups. However, the number of
adverse events showed no significant difference between
the two groups (data not shown). The mean lymphocyte
count in the dose-reduced group tended to be lower
than in the dose-maintained group on day 14 (900/m2
versus 1500/m2, p = 0.05). Mean platelet count in the
dose-reduced group tended to be lower on day 14
(16.4 × 104/m2 versus 23.4 × 104/m2, p = 0.09), but
recovered gradually following dose reduction or discon-
tinuation. On the other hand, platelet count in the dose-
maintained group decreased gradually and tended to be
lower than in the dose-reduced group on day 28
(16.6 × 104/m2 versus 11.7 × 104/m2, p = 0.06).
Analysis of ABCG2 and FLT3 polymorphism
To investigate the relationship between hematotoxicity
and gene polymorphisms associated with sunitinib, we
analyzed two genotypes in 36 patients who gave in-
formed consent. Genetic analysis for the ABCG2 poly-
morphism and FLT3 polymorphism in the two groups
are shown in Table 5. Among 36 patients, 25 patients
(69%) were in the dose-reduced group, and 11 (31%) in
the dose-maintained group. Genetic analysis found no
significant difference in ABCG2 421 C/A polymorphism
between the two groups (dose-reduced group: wild-type
allele n = 12, variant allele n = 13; dose-maintained
group: wild-type allele n = 6, variant allele n = 5;
p = 1.00). We analyzed laboratory data related to
ABCG2 polymorphism (Table 6). The mean lymphocyte
count of patients with the ABCG2 variant allele tended
to be lower than those with the wild-type allele on day
14 (700/m2 versus 1200/m2, p = 0.08). The mean platelet
count showed no significant difference between the two
groups on day 14 (13.5 × 104/m2 versus 17.9 × 104/m2,
p = 0.24). The lactate dehydrogenase (LDH) level in the
group with ABCG2 variant allele was significantly higher
than wild-type allele group on day 14 (537.7 IU/L versus
324.5 IU/L, p = 0.04). Among those with the variant al-
lele, 2 patients with the ABCG2 421 genotype homozy-
gous for the A allele required dose reduction in the first
cycle. One was treated with a starting dose of 50 mg/
day. He later developed a high fever, grade 2 leukopenia,
and grade 3 thrombocytopenia in the second week of
the first cycle. The other patient was treated at a
starting dose of 25 mg/day. She developed grade 2
thrombocytopenia in the third week of the first cycle.
The frequency of the FLT3 738 T/C polymorphism
was significantly higher in the dose-reduced group
(wild-type allele n = 11, heterozygous variant allele
n = 14) than in the dose-maintained group (wild-type
n = 9, heterozygous variant allele n = 2, p = 0.04). We
analyzed laboratory data related to FLT3 polymorphism
(Table 6). The mean platelet count of patients with the
FLT3 variant allele was significantly lower than wild-type
allele on day 14 (11.7 × 104/m2 versus 18.9 × 104/m2,
Table 4 Laboratory data during the first cycle
Group Baseline p Day 7 p Day 14 p Day 21 p Day 28 p Day 42 p
Lymphocyte count ×103 /μL Dose-
reduced
1.2 ± 0.6 0.08 1.3 ± 0.1 0.14 0.9 ± 0.1 <0.01 0.9 ± 0.1 0.17 1.1 ± 0.1 0.17 1.2 ± 0.1 0.68
Dose-
maintained
1.4 ± 0.1 1.6 ± 0.1 1.4 ± 0.1 1.2 ± 0.2 1.2 ± 0.1 1.3 ± 0.1
Platelet count ×104 /μL Dose-reduced 30.1 ± 2.0 0.80 26.8 ± 2.0 0.89 15.9 ± 1.2 0.04 12.0 ± 1.4 0.17 16.8 ± 1.8 0.01 24.1 ± 1.9 0.28
Dose-
maintained
30.9 ± 2.6 27.3 ± 3.1 22.0 ± 2.4 15.6 ± 2.1 11.6 ± 1.0 20.8 ± 2.3
Data are expressed as mean ± SE.
Table 5 Genetic analysis for the two groups
Genotypes Dose-reduced group Dose-maintained group Univariate analysis
n = 25 n = 11 p value
ABCG2 421 C/A, n (%) Wild-type allele 12 (67) 6 (33) 1.00
Variant allele 13 (72) 5 (28)
FLT3 738 T/C, n (%) Wild-type allele 11 (55) 9 (45) 0.04
Variant allele 14 (88) 2 (12)
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p = 0.04). The mean lymphocyte count showed no sig-
nificant relation to the FLT3 genotypes on day 14 (800/
m2 versus 1100/m2, p = 0.20). The Asparate aminotrans-
ferase (AST) and Alkaline phosphatase (ALP) of patients
with FLT3 variant allele were significantly higher than wild-
type allele on day 14 (73.6 IU/L versus 38.7 IU/L, p = 0.04,
454.9 IU/L versus 299.7 IU/L, p = 0.03, respectively). Two
patients in the dose-maintained group had the FLT3 738
C-allele. Both patients were given 50 mg/day during the
first cycle. One was a 40 year-old obese (Body Mass
Index 33 kg/m2) woman. She had grade 2
thrombocytopenia during the first cycle and grade 3
thrombocytopenia at the end of the second cycle, when
sunitinib was then discontinued. The other patient was a
56 year-old man. He had grade 1 thrombocytopenia on
day 14 of the first cycle and continued sunitinib therapy.
Efficacy
The median follow-up period was 15.7 (range 0.9 to 78.7)
months. The median TTF in all patients was estimated to
be 7.0 (range 0.1 to 37.6) months. The most common
reason for discontinuation was adverse events (51%).
The TTF tended to be shorter in the dose-reduced
group than in the dose-maintained group (6.9 months
versus 9.0 months, p = 0.23). The median TTF in patients
who had early-onset thrombocytopenia tended to be
longer than those without early-onset thrombocytopenia
in either group (data not shown). The median TTF
according to the gene polymorphism in both ABCG2 and
FLT3 showed no significant differences.
Discussion
In the present study, we retrospectively analyzed
sunitinib-induced early-onset hematotoxicity. Analysis
of hematological adverse events during the first cycle
in all patients showed a high incidence of hypoalbu-
minemia, thrombocytopenia, anemia, and elevated
AST. During the first 2 weeks of the first cycle, the
most common adverse events were hypoalbuminemia,
anemia, increased creatinine, and thrombocytopenia.
An expanded access trial reported thrombocytopenia
(all grade 22%, grade 3/4 8%), anemia (all grade 15%,
grade 3/4 4%), and neutropenia (all grade 15%, grade
3/4 6%) as common hematological adverse events
[13]. A Japanese subgroup analysis showed a high in-
cidence of thrombocytopenia (first-line population
and pretreated population: 96% and 88%, respectively),
leukopenia (88% and 85%), and lymphocytopenia (76%
and 58%) [5]. The incidence of thrombocytopenia in
our subjects was the same as that reported by a
Japanese subgroup analysis [5], while the incidence of
hypoalbuminemia and anemia was higher. A possible
reason is the higher proportion of poor risk patients
in our study than in previous studies [1, 13], since
Table 6 Laboratory data during the first cycle related to ABCG2 and FLT3 genotypes
Genotype Baseline p Day 7 p Day 14 p Day 28 p Day 42 p
Lymphocyte
count ×103 /μL
ABCG2 421 C/A Wild-type 1.3 ± 0.1 0.88 1.6 ± 0.2 0.22 1.2 ± 0.2 0.08 1.3 ± 0.1 0.24 1.3 ± 0.1 0.57
Variant 1.4 ± 0.1 1.3 ± 0.2 0.7 ± 0.1 1.1 ± 0.1 1.2 ± 0.1
FLT3 738 T/C Wild-type 1.2 ± 0.1 0.59 1.4 ± 0.1 0.98 1.1 ± 0.2 0.20 1.1 ± 0.1 0.31 1.1 ± 0.1 0.16
Variant 1.3 ± 0.1 1.4 ± 0.2 0.8 ± 0.1 1.3 ± 0.2 1.4 ± 0.1
Platelet count
×104 /μL
ABCG2 421 C/A Wild-type 29.5 ± 4.0 0.78 23.5 ± 3.3 0.78 17.9 ± 3.0 0.24 16.2 ± 2.7 0.99 23.5 ± 2.6 0.34
Variant 28.4 ± 1.3 24.6 ± 1.8 13.5 ± 2.2 16.1 ± 2.7 20.4 ± 1.7
FLT3 738 T/C Wild-type 30.3 ± 3.0 0.40 26.2 ± 2.8 0.16 18.9 ± 3.0 0.04 16.3 ± 2.9 0.99 21.4 ± 2.4 0.66




ABCG2 421 C/A Wild-type 32.7 ± 4.6 0.10 42.0 ± 8.9 0.28 45.1 ± 6.9 0.23 36.3 ± 4.4 0.47 28.7 ± 3.4 0.33
Variant 23.8 ± 2.4 31.6 ± 2.6 63.7 ± 13.7 31.6 ± 4.6 24.4 ± 2.7
FLT3 738 T/C Wild-type 27.4 ± 3.9 0.71 38.1 ± 7.6 0.72 38.7 ± 4.6 0.04 35.0 ± 4.6 0.72 24.7 ± 2.4 0.36




ABCG2 421 C/A Wild-type 223.6 ± 17.1 0.88 263.9 ± 27.9 0.36 324.5 ± 32.2 0.04 270.7 ± 20.0 0.47 229.1 ± 14.4 0.96
Variant 228.6 ± 27.4 315.5 ± 47.8 537.7 ± 90.9 295.9 ± 27.9 227.9 ± 17.5
FLT3 738 T/C Wild-type 221.8 ± 15.6 0.78 286.7 ± 39.1 0.90 422.9 ± 85.0 0.81 287.6 ± 19.8 0.79 235.4 ± 15.5 0.50




ABCG2 421 C/A Wild-type 462.5 ± 128.4 0.84 520.7 ± 207.3 0.65 342.3 ± 33.9 0.35 504.3 ± 119.8 0.73 415.4 ± 92.3 0.87
Variant 426.4 ± 121.6 418.0 ± 87.2 412.4 ± 65.4 452.8 ± 88.3 440.7 ± 120.8
FLT3 738 T/C Wild-type 422.4 ± 117.3 0.78 509.4 ± 194.3 0.70 299.7 ± 19.7 0.03 466.6 ± 114.2 0.87 384.4 ± 89.8 0.54
Variant 472.1 ± 134.4 423.9 ± 93.7 454.9 ± 66.2 490.3 ± 79.7 479.1 ± 124.9
Data are expressed as mean ± SE.
Kato et al. BMC Cancer  (2017) 17:214 Page 7 of 10
60–70% of our patients had anemia and/or hypoalbu-
minemia prior to sunitinib treatment.
Generally, dose adjustment for chemotherapeutic drugs
is decided based on several factors including BSA, renal
function, and liver function. However, for molecular-
targeted agents, there are no established criteria to decide
the starting and maintenance doses. In the clinical setting,
the starting dose is decided by the attending physician
considering patient characteristics including sex, perform-
ance status, and physical constitution, and sometimes
requires adjustment because of hematotoxicity or other
toxicities. Previous reports suggest that the RDI of the
whole cycle affects efficacy and toxicity of sunitinib
[14, 15]. Japanese patients have difficulties maintain-
ing the starting sunitinib dose during the first cycle,
and a few reports described dose changes during the
dosing period. In our institute, the most common rea-
son for dose reduction or discontinuation during the
first cycle is hematotoxicity. In our subjects, sunitinib
dose in the last 2 weeks of the first cycle was significantly
reduced compared with that in the first 2 weeks. Increased
exposure to sunitinib is supposed to increase the inci-
dence or severity of hematotoxicity. Therefore, our
study focused on the group that developed early-onset
hematological adverse events and required dose reduc-
tion. The dose-reduced group was older with a lower
BSA than the dose-maintained group, but the starting
dose was similar in both groups. The meta-analysis
conducted by Houk et al. [16] suggests that individual
covariates (race, gender, body weight, and ECOG
Performance status score) have minimal effects on the
pharmacokinetics of sunitinib and its primary metabol-
ite (SU12662). The early-onset hematological adverse
events in the dose-reduced group were lymphocytope-
nia and thrombocytopenia. In this group, lymphocyte
and thrombocyte counts decreased in the second to
third week and took a few weeks to recover to the base-
line level. In the dose-maintained group, however,
thrombocyte counts decreased gradually during dosing
and were significantly lower than that in the dose-
reduced group on day 28. Previous studies reported a
pharmacogenetic association with hematological ad-
verse events on day 28 or day 42 of the treatment cycle
[11, 12]. Our result suggests that laboratory data on day
28 or day 42 may include not only the lowest levels in
patients who do not need dose reduction or discontinu-
ation, but also the recovered levels after the dose has
been modified according to toxicity.
Subgroup analysis in patients with clear cell RCC
showed no significant difference in the incidence of
hematotoxicity between the dose-reduced group and the
dose-maintained group. In this study, approximately
80% of patients with clear cell histology have previously
undergone a nephrectomy. Thirty-one patients started
sunitinib treatment in the diagnosis of imaging modality
without histological diagnosis. Patients with unde-
termined histology tended to have a lower KPS and a
higher rate of MSKCC poor risk than patients with clear
cell RCC [KPS: 88.4% versus 92.3%, MSKCC poor risk
group: n = 13 (42%) versus 10 (21%)]. Surgery or biopsy
is needed to evaluate histological subtype although
biopsy would be a relatively invasive procedure for
patients. We assumed that the physicians might avoid
biopsy particularly in patients with low performance
status due to disease progression or comorbidities. We
considered that patients with undetermined histology
might include patients with advanced clear cell RCC and
result of analysis of clear cell RCC subgroup would
include selective bias.
In this study, 33 patients in the dose-reduced group
continued sunitinib treatment in the second cycle.
Although the starting dose for the second cycle was
reduced, a higher dose compared to the first cycle was
maintained for the last 2 weeks during the second cycle.
In these patients, the mean thrombocyte count during
the second cycle was stable (225.0 × 104/m2 during the
first 2 weeks, and 220.3 × 104/m2 during the last 2 weeks,
p = 0.81). These results indicate that dose adjustment
based on early-onset hematotoxicity in the first cycle
avoids treatment discontinuation. Appropriate dose
modification during the early cycles of sunitinib treatment
is potentially useful in identifying sunitinib-resistant pa-
tients who need alternative TKI therapy or a new therapy
with different mechanisms of action such as the mamma-
lian target of rapamycin (mTOR) inhibitor, or sunitinib-
intolerant patients who require therapy with different
adverse event profiles.
Our analysis showed a high incidence of hematological
adverse events compared with non-Asian populations
[1, 13], with characteristic changes in lymphocyte and
thrombocyte counts in the early treatment period. Based
on these results, we analyzed the ABCG2 genotype which
is related to a high exposure of sunitinib in the Asian
population, and the FLT3 genotype which is associated
with sunitinib-induced myelosuppression. The rate of
ABCG2 421 C/A polymorphism showed no significant
difference between the dose-reduced group and dose-
maintained group. Analysis of the laboratory data of those
with the ABCG2 gene polymorphism showed that the
early-onset of lymphocytopenia and elevated LDH tend to
be seen in patients with the ABCG2 variant allele, but not
thrombocytopenia. Among patients having the ABCG2
421 A-allele, two patients with a homozygous genotype
required dose reduction during the first cycle. Both pa-
tients developed moderate to severe hematological adverse
events. The frequency of the ABCG2 421 AA genotype is
7% and that of ABCG2 421 CA is 39% in Japanese popula-
tion [17]. Mizuno et al. [9] demonstrated the association
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of plasma sunitinib concentration with the intestinal
absorption process, and suggested that the ABCG2 421 A-
allele is related to increased sunitinib exposure. Miura et
al. [10] reported a patient with the ABCG2 421 AA geno-
type who had a high concentration of sunitinib on day 14
of the first cycle and severe adverse events including
thrombocytopenia. Our study found no relationship be-
tween the ABCG2 genotypes and thrombocytopenia. A
possible reason may be the small number of patients with
homozygous alleles. Furthermore, unlike previous studies,
our study was not designed to examine the relationship
between the ABCG2 genotype with pharmacokinetics, and
hence may result in selection bias. The frequency of the
FLT3 738 C-allele carriers was significantly higher in the
dose-reduced group than in the dose-maintained group.
Kumar et al. [11] investigated kinase selectivity and the
effect on cell proliferation of the three TKIs (sunitinib,
sorafenib, and pazopanib), and suggested that the strong
activity of sunitinib against c-kit and FLT3 may provide a
plausible explanation for the high incidence of myelosup-
pression observed in clinical treatment. Van Erp et al. [12]
investigated the relationship between the FLT3 738 geno-
type and thrombocyte count during the 4 weeks of the
first cycle, and showed a significant decrease in thrombo-
cyte count in the FLT3 738 C-allele carriers compared
with FLT3 TT individuals. Their study showed approxi-
mately 30% of patients developed thrombocytopenia dur-
ing the first cycle, which was much lower than that in the
Asian population. In the present study, the thrombocyte
count on day 28 of the first cycle was significantly
lower in the dose-maintained group than in the dose-
reduced group, consistent with a previous report [12].
The thrombocyte count on day 14 of the first cycle
was significant lower in the dose-reduced group than
in the dose-maintained group. Analysis of laboratory
data in those patients with the FLT3 gene polymorph-
ism showed that the thrombocyte count on day 14
was significantly lower than in patients with the wild-type
allele. We also analyzed the laboratory data and SNPs of
three patients who were treated with a modified schedule
of “2 weeks on and 1 week off.” The mean thrombocyte
count on day 14 of the two patients with the FLT3 738 TC
(11.2 × 104/m2) was lower than that in one patient with
FLT3 738 TT (15.3 × 104/m2). One of the 2 patients
having the FLT3 738 C-allele in the dose-maintained
group was a 40 year-old obese woman. She had severe
thrombocytopenia at the end of the second cycle, and
sunitinib was discontinued. Increased clearance with in-
creasing body weight was reported for TKIs [18], and a
previous report evaluated the effect of body weight on the
pharmacokinetics of sunitinib [12]. We speculate that
FLT3 738 C-allele carriers tend to be more susceptible to
early-onset thrombocytopenia and require dose reduction.
Profiles of early-onset of hematotoxicity related to gene
polymorphism were different between ABCG2 and FLT3
genotypes. We assumed that this difference might occur
due to pharmacokinetics effects related to ABCG2 poly-
morphism and the pharmacodynamics effects related to
FLT3. We recommend that monitoring of laboratory data
during the early dosing period is required to analyze the
relationship between hematotoxicity with gene poly-
morphism, especially in Asian populations. Future studies
should evaluate whether there is an association between
these two SNPs and non-hematological adverse events
such as hypertension and fatigue which can be a major
problem in the clinical setting.
The median TTF of all patients was estimated to be
7.0 months. The most common reason for discontinuation
of sunitinib treatment was adverse events. TTF in the dose-
reduced group tended to be shorter compared to the dose-
maintained group. The median TTF tended to be longer in
patients who developed early-onset thrombocytopenia than
in those without thrombocytopenia (data not shown). A
previous study reported thrombocytopenia as a predictive
biomarker of prolonged survival [19]. In the present
retrospective study, discontinuation of sunitinib treat-
ment was decided by the clinical doctors. Together
with the small number of patients studied, selection
bias may have influenced the result of TTF. Never-
theless, we propose that patients with early-onset
thrombocytopenia should undergo dose reduction or a
drug holiday, and continue treatment with adjusted
doses, which may prolong the TTF. A prospective
study with RDI analysis is warranted to determine the
efficacy of treatment strategy with dose modification
using thrombocytopenia as a biomarker. Though
ABCG2 and FLT3 genotypes were not identified as
prognostic factors in this study, dose adjustment based
on these specific SNPs may prolong the period of
sunitinib treatment.
Our study has several limitations. First, it was a retro-
spective study with a small number of cases and poten-
tial selection bias. Second, this study did not assess the
plasma concentration of sunitinib, and hence lacks
pharmacokinetics data. Third, not all the patients under-
went SNP analysis because some patients were lost to
follow-up or refused genetic analysis.
Conclusions
In conclusion, our study showed that many patients
need dose reduction during the first cycle of sunitinib,
as these patients developed thrombocytopenia and lym-
phocytopenia during the early period of the first cycle.
We consider that dose adjustment based on early-onset
toxicity may prolong the period of sunitinib treatment.
Further studies with longer follow-up are warranted to
verify whether sunitinib dose adjustment based on early-
onset toxicity improves the prognosis for RCC.
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